Beigene, Ltd. (NASDAQ:ONC – Get Free Report) COO Xiaobin Wu sold 30,654 shares of the company’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $240.74, for a total transaction of $7,379,643.96. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.
Xiaobin Wu also recently made the following trade(s):
- On Thursday, February 20th, Xiaobin Wu sold 21,267 shares of Beigene stock. The shares were sold at an average price of $240.07, for a total transaction of $5,105,568.69.
Beigene Stock Up 4.6 %
Shares of NASDAQ:ONC opened at $255.37 on Friday. The stock has a market cap of $24.99 billion, a PE ratio of -30.99, a PEG ratio of 7.73 and a beta of 0.63. The company has a quick ratio of 1.72, a current ratio of 1.93 and a debt-to-equity ratio of 0.05. Beigene, Ltd. has a 12 month low of $126.97 and a 12 month high of $260.98.
Beigene Company Profile
BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.
Read More
- Five stocks we like better than Beigene
- Investing in Construction Stocks
- Unity Stock: Is a True Turnaround Finally Taking Shape?
- Following Congress Stock Trades
- DuPont’s Electronics Spinoff: The Start of Something Big
- What Does a Stock Split Mean?
- The Trade Desk Crashes on Earnings, But Growth Catalysts Persist
Receive News & Ratings for Beigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene and related companies with MarketBeat.com's FREE daily email newsletter.
